- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01073631
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea
May 31, 2012 updated by: Pfizer
Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet
This is a non-interventional study of voriconazole tablet in Korea which is mandated by the Korean government agency.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
543
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who are indicated for voriconazole tablet according to the drug package insert.
Description
Inclusion Criteria:
- Patients who are indicated for voriconazole table according to the drug package insert.
Exclusion Criteria:
- None.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
Patients who are indicated for use of voriconazole tablet.
|
200 mg PO bid (orally, twice a day)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable
Time Frame: Baseline (Day 1) up to 2.1 Years
|
Clinical response defined as: Cure=resolution of all baseline signs and symptoms of fungal infection(s); Improvement=lessening of baseline signs and symptoms or absence of one or more, but not all baseline findings; Failure=no improvement or deterioration of baseline condition; Unevaluable=incomplete therapy (efficacy could not be evaluated or discontinuation was not followed up).
|
Baseline (Day 1) up to 2.1 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Cultivated Strain Mycological Response: Eradication, Persistence, Superinfection, or Not Evaluable
Time Frame: Baseline (Day 1) up to 2.1 Years
|
In case cultivation performed, cultivated strain before and after Vfend administration recorded, and the improvement of mycological outcomes after administration evaluated.
Mycological response defined as: Eradication=absence of signs and symptoms of fungal infection; Persistence=(no eradication) presence of fungal infection; Superinfection=existence of different strains from strains separated prior to study treatment; Not evaluable=a follow-up mycological cultivation not performed.
|
Baseline (Day 1) up to 2.1 Years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
February 22, 2010
First Submitted That Met QC Criteria
February 22, 2010
First Posted (Estimate)
February 23, 2010
Study Record Updates
Last Update Posted (Estimate)
June 7, 2012
Last Update Submitted That Met QC Criteria
May 31, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections and Mycoses
- Mycoses
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Voriconazole
Other Study ID Numbers
- A1501068
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Serious Fungal Infections
-
PfizerCompletedNon-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IVSerious Fungal Infections
-
WockhardtQuintiles, Inc.CompletedSerious Gram-negative InfectionsUnited States
-
People's Hospital of Zhengzhou UniversityRecruitingFactors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly PatientsInvasive Fungal InfectionChina
-
Nantes University HospitalCompletedInvasive Fungal InfectionFrance
-
Astellas Pharma Global Development, Inc.CompletedInvasive Fungal InfectionUnited States
-
Asan Medical CenterWithdrawnInvasive Fungal InfectionKorea, Republic of
-
Hospital Universitario La FeCompletedFungal Invasive DiseaseSpain
-
Radboud University Medical CenterCompletedInvasive Fungal InfectionNetherlands
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedInvasive Fungal DiseaseChina
-
Peking Union Medical College HospitalRecruiting
Clinical Trials on voriconazole tablet
-
dingshifangShandong Provincial Hospital; Qianfoshan Hospital; Jinan Military General Hospital and other collaboratorsUnknownInvasive Pulmonary AspergillosisChina
-
Seoul National University HospitalCompletedHealthy VolunteersKorea, Republic of
-
PfizerCompletedScedosporium Infection
-
PfizerCompleted
-
PfizerUniversity of Southern CaliforniaCompleted
-
PfizerCompletedCandidemia | CandidiasisUnited States
-
Chong Kun Dang PharmaceuticalCompletedFungal Infections | Candida Infections | Aspergillus InfectionsKorea, Republic of
-
Sara BotrosCompleted
-
Jan-Willem C AlffenaarUMC Utrecht; Erasmus Medical Center; Amsterdam UMC, location VUmc; Academisch Medisch... and other collaboratorsCompletedInvasive Fungal Infection | Hematological MalignancyNetherlands
-
The Affiliated Hospital of Qingdao UniversityCompleted